Home Cart Sign in  
Chemical Structure| 501364-82-5 Chemical Structure| 501364-82-5

Structure of INO-1001
CAS No.: 501364-82-5

Chemical Structure| 501364-82-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

INO-1001 is an isoindolinone derivative and potent inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with chemosensitization and radiosensitization properties. INO-1001 inhibits PARP, which may result in inhibition of tumor cell DNA repair mechanisms and, so, tumor cell resistance to chemotherapy and radiation therapy. PARP enzymes are activated by DNA breaks and have been implicated in the repair of DNA single-strand breaks (SSB). NOTE: as of 7/29/2016, many vendors are selling INO-1001 with wrong structure (3-aminobenzamide, CAS# 3544-24-9)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of INO-1001

CAS No. :501364-82-5
Formula : C23H25N3O4S
M.W : 439.53
SMILES Code : O=S(C1=CC(C2)=C(C3=C2C4=C(C(N3)=O)C=CC=C4)C=C1)(NCCCN5CCOCC5)=O
MDL No. :MFCD19443171
InChI Key :LTZVLHHIAUKGBP-UHFFFAOYSA-N
Pubchem ID :9889396

Safety of INO-1001

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of INO-1001

epigenetics
DNA

Isoform Comparison

Biological Activity

Description
INO-1001, a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor, heightens radiation sensitivity and augments radiation-induced cell death by disrupting DNA repair mechanisms, leading to necrotic cell demise[1].

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Transgenic R6/2 mice Huntington's disease model Intraperitoneal injection 10 mg/kg/day Daily, starting from 4 weeks of age INO-1001-treated R6/2 mice survived longer and displayed less severe signs of neurological dysfunction than the vehicle treated ones. Striatal atrophy was reduced, and there was a significant increase in activated CREB and BDNF in the striatal spiny neurons. PLoS One. 2015 Aug 7;10(8):e0134482
Mice R6/2 mouse model Intraperitoneal injection 10 mg/kg/day Twice daily, starting from 4 weeks of age until sacrifice To investigate the effects of PARP-1 inhibition on CBP localization, by reducing CBP sequestration into the NIIs, and thus decreasing cellular toxicity resulting from it. Moreover, we studied the effects of the compound on calretinin and parvalbumin containing striatal cells, two subsets of interneurons that are particularly vulnerable to HD. Front Neuroanat. 2017 Aug 2;11:61

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00271167 Heart Diseases|Postoperative C... More >>omplications Less << PHASE2 TERMINATED 2025-06-06 Beth Israel Deaconess Medical ... More >>Center, Boston, Massachusetts, 02215, United States|University of Oklahoma, Oklahoma, Oklahoma, 73152, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Methodist Hospital, Houston, Texas, 77030, United States|Sydney, New South Wales, Australia|Ashford Cardiac Clinic / Adelaide Cardiac, Adelaide, South Australia, Australia|St. Vincent's Hospital, Melbourne, Victoria, 3065, Australia|Royal Perth Hospital, Perth, Western Australia, 6000, Australia|Care Hospital, Hyderabad, India|Escorts Heart Institute and Research Centre, New Delhi, 110029, India|Wolfson Medical Centre, Holon, 58100, Israel|Jerusalem, Israel Less <<
NCT00271765 Acute Myocardial Infarction PHASE2 COMPLETED 2025-06-06 Holy Cross Hospital, Fort Laud... More >>erdale, Florida, 33308, United States|Porter Hospital, Valparaiso, Indiana, 46383, United States|St. Paul Heart Clinic, St. Paul, Minnesota, 55102, United States|Newark, New Jersey, United States|Toledo Hospital, Toledo, Ohio, 43606, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Black Hills Cardiovascular Research, Rapid City, South Dakota, 57701, United States|Burlington, Vermont, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|West Virginia University, Morgantown, West Virginia, 26506, United States|Rambam Medical Center, Haifa, 31096, Israel|Meir Medical Center, Kfar Saba, 95847, Israel|Hasharon Medical Center, Petach Tikva, 49100, Israel|Rabin Medical Center, Petach Tikva, 49100, Israel|Rehovot, Israel|Assaf Harofe Medical Centre, Zerifin, Israel Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.38mL

2.28mL

1.14mL

22.75mL

4.55mL

2.28mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories